Allogenic mesenchymal stem cell-based products for veterinary use: specific questions on tumorigenicity

Current version

PDF iconQuestions and Answers

Reference number

EMA/CVMP/ADVENT/791465/2016

Published21/11/2017
Keywordsstem cell, veterinary, tumorigenicity
DescriptionThe guidance, in the form of questions and answers, addresses concerns raised by manufacturers and authorities regarding the tumorigenicity (ability to form tumours) of allogenic stem cell therpies in the veterinary sector. Allogenic stem cell-based veterinary medicines originate from tissues (such as bone marrow or fat) from a donor from the same species of animal, not from the recipient of the cells. The guidance was developed following a review of scientific information in relation to stem cell products intended for veterinary use.


Related content


Topics

How useful was this page?

Add your rating
Average
1 rating